Albig Allan R, Schiemann William P
Program in Cell Biology, Department of Pediatrics, National Jewish Medical and Research Center, Denver, CO 80206, USA.
Mol Biol Cell. 2005 Feb;16(2):609-25. doi: 10.1091/mbc.e04-06-0479. Epub 2004 Nov 17.
Tubulogenesis by epithelial cells regulates kidney, lung, and mammary development, whereas that by endothelial cells regulates vascular development. Although functionally dissimilar, the processes necessary for tubulation by epithelial and endothelial cells are very similar. We performed microarray analysis to further our understanding of tubulogenesis and observed a robust induction of regulator of G protein signaling 4 (RGS4) mRNA expression solely in tubulating cells, thereby implicating RGS4 as a potential regulator of tubulogenesis. Accordingly, RGS4 overexpression delayed and altered lung epithelial cell tubulation by selectively inhibiting G protein-mediated p38 MAPK activation, and, consequently, by reducing epithelial cell proliferation, migration, and expression of vascular endothelial growth factor (VEGF). The tubulogenic defects imparted by RGS4 in epithelial cells, including its reduction in VEGF expression, were rescued by overexpression of constitutively active MKK6, an activator of p38 MAPK. Similarly, RGS4 overexpression abrogated endothelial cell angiogenic sprouting by inhibiting their synthesis of DNA and invasion through synthetic basement membranes. We further show that RGS4 expression antagonized VEGF stimulation of DNA synthesis and extracellular signal-regulated kinase (ERK)1/ERK2 and p38 MAPK activation as well as ERK1/ERK2 activation stimulated by endothelin-1 and angiotensin II. RGS4 had no effect on the phosphorylation of Smad1 and Smad2 by bone morphogenic protein-7 and transforming growth factor-beta, respectively, indicating that RGS4 selectively inhibits G protein and VEGF signaling in endothelial cells. Finally, we found that RGS4 reduced endothelial cell response to VEGF by decreasing VEGF receptor-2 (KDR) expression. We therefore propose RGS4 as a novel antagonist of epithelial and endothelial cell tubulogenesis that selectively antagonizes intracellular signaling by G proteins and VEGF, thereby inhibiting cell proliferation, migration, and invasion, and VEGF and KDR expression.
上皮细胞的管形成调节肾脏、肺和乳腺的发育,而内皮细胞的管形成调节血管发育。尽管功能不同,但上皮细胞和内皮细胞形成管所需的过程非常相似。我们进行了微阵列分析,以进一步了解管形成,并观察到仅在形成管的细胞中G蛋白信号调节因子4(RGS4)mRNA表达有强烈诱导,从而表明RGS4是管形成的潜在调节因子。相应地,RGS4过表达通过选择性抑制G蛋白介导的p38丝裂原活化蛋白激酶(MAPK)激活,进而通过减少上皮细胞增殖、迁移和血管内皮生长因子(VEGF)表达,延迟并改变了肺上皮细胞的管形成。RGS4在上皮细胞中造成的管形成缺陷,包括其VEGF表达的降低,通过组成型活性MKK6(p38 MAPK的激活剂)的过表达得以挽救。同样,RGS4过表达通过抑制内皮细胞的DNA合成和通过合成基底膜的侵袭,消除了内皮细胞的血管生成芽生。我们进一步表明,RGS4表达拮抗VEGF对DNA合成以及细胞外信号调节激酶(ERK)1/ERK2和p38 MAPK激活的刺激,以及内皮素-1和血管紧张素II刺激的ERK1/ERK2激活。RGS4分别对骨形态发生蛋白-7和转化生长因子-β诱导的Smad1和Smad2磷酸化没有影响,表明RGS4选择性抑制内皮细胞中的G蛋白和VEGF信号传导。最后,我们发现RGS4通过降低VEGF受体-2(KDR)表达来降低内皮细胞对VEGF的反应。因此,我们提出RGS4是上皮细胞和内皮细胞管形成的新型拮抗剂,它选择性拮抗G蛋白和VEGF的细胞内信号传导,从而抑制细胞增殖、迁移和侵袭以及VEGF和KDR表达。